The Relationship between the Spanish Government and the Pharmaceutical Company (Gilead) during the Hepatitis C crisis in Spain


  • Serena Alonso García University Carlos III (Madrid)



Gilead, Hepatitis C, Patent, Private-Self Regulation, Sovaldi™, TRIPS Agreement, Welfare States


This research note investigates the pattern of governance that underpinned the management of the Hepatitis C crisis that took place in Spain in 2014. By navigating through the facts, one can see how the private interests of a multinational company – Gilead, the patent holder of the new treatment for the Hepatitis C virus – were capable of exerting pressure on Spain, a highly developed state, to a point where the government applied measures that contradicted the country’s Constitution and caused 4000 avoidable deaths. Different theories of governance will be used to try to explain the new dynamics. The main conclusion of this research note is that the power of the state is diminishing in many cases, and that this has consequences for the public interest and the population in general.

Author Biography

Serena Alonso García, University Carlos III (Madrid)

Serena Alonso is a student at the University Carlos III (Madrid). She is studying for a double degree in Law and Political Science and she will be moving to the United Kingdom the following academic year in order to continue her studies at the University of Bristol. She has a strong interest in human rights and international affairs, having been an intern for the United Nations in summer of 2018 and for the Spanish Ministry of Justice in summer of 2019.


Abbott, Kenneth and Duncan Snidal. 2009. “The Governance Triangle.” In The Politics of Global Regulation, edited by Walter Mattli and Ngaire Woods, 44-88. Princeton: Princeton University Press.

Alonso, Adrián. 2015. “Marketing Analysis for New-Generation Medicines for Hepatitis C.” Bachelor Thesis. (29 October 2017).

Brahm, Eric. 2005. “International Regimes”. In Beyond Intractability, edited by Guy Burgess and Heidi Burgess. Conflict Information Consortium, University of Colorado, Boulder. Posted: September 2005. (24 June 2019).

Campillo, Carlos, Sandra García and Enrique Bernal. 2016. “The Merry-go-round of Approval, Pricing and Reimbursement of Drugs against the Hepatitis C Virus Infection in Spain.” Health Policy 120: 975-981.

El Mundo. 2015. “Afectados por la Hepatitis C Presentan una Querella contra Ana Mato por 'Dejar Morir' a 4.000 Pacientes.” (05 August 2019).

Knill, Christoph and Dirk Lehmkuhl. 2002. “Private Actors and the State: Internationalization and Changing Patterns of Governance.” Governance, 15, no. 1: 41-63.

La Caixa. 2016. “Hepatitis C: ‘The New Battleground for Access to Essential Medicines.” (24 May 2019).

Ministry of Health, Social Services and Equality. 2015. Strategic Plan for Tackling Hepatitis C in the Spanish National Health System. 21 May. Madrid: Office of the Secretary for Health and Consumer Affairs.

Ortega, Eduardo and Jesús Vicioso. 2015. “Hepatitis C, Manual para Entender la Polémica.” Revista Médica 226. (24 June 2019).

Pérez, Oliva Milagros. 2017. “El Alto Coste de un Pelotazo Farmacéutico.” El País. (24 June 2019).

Sagasti, Francisco and Keith Bezanson. 2004. “Global Public Goods: opportunities and threats.” The Courier 202: 15-16.

Spanish Constitution. 1978.

World Health Organization. 2019. “Hepatitis C”. (24 June 2019).

World Trade Organization. 2006. “Philosophy: TRIPS Attempts to Strike a Balance.” (24 June 2019).




How to Cite

Alonso García, Serena. 2020. “The Relationship Between the Spanish Government and the Pharmaceutical Company (Gilead) During the Hepatitis C Crisis in Spain”. Politikon: The IAPSS Journal of Political Science 45 (June). Online:90-98.



Research notes